Beta Alethine in Treating Patients With Low-Grade Lymphoma
NCT ID: NCT00007839
Last Updated: 2013-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
INTERVENTIONAL
2000-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: Phase I/II trial to study the effectiveness of beta alethine in treating patients who have low-grade lymphoma.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the antitumor effects of low-dose beta-alethine in patients with low grade B-cell lymphoma.
* Assess the effects of this regimen on delayed-type hypersensitivity in these patients.
* Assess the safety of this regimen in this patient population.
OUTLINE: This is an multicenter study.
Patients receive low-dose beta-alethine subcutaneously once every 2 weeks for a total of 6 doses in the absence of unacceptable toxicity. Patients with no evidence of tumor progression may receive additional courses of therapy.
Patients are followed for 2 weeks from the last dose or for a minimum of 30 days if they withdraw due to an adverse event.
PROJECTED ACCRUAL: Approximately 13-37 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
beta alethine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed low grade B-cell lymphoma
* Measurable residual disease after maximal response to prior chemotherapy OR
* Indolent disease not yet requiring therapy
* No congenital immunodeficiency associated lymphoma
* No primary lymphoma of the brain
* No active brain involvement or leptomeningeal disease NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* Karnofsky 50-100%
Life expectancy:
* At least 4 months
Hematopoietic:
* Neutrophil count at least 1,500/mm3
* Platelet count at least 100,000/mm3
* Hemoglobin at least 10 g/dL
Hepatic:
* Bilirubin less than 2.0 mg/dL
* SGOT/SGPT no greater than 2.5 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present)
Renal:
* Creatinine no greater than 2.0 mg/dL
* Calculated creatinine clearance at least 60 mL/min
Cardiovascular:
* No uncontrolled angina, heart failure, or arrhythmia
* No acute changes on EKG
Other:
* Not pregnant or nursing
* Fertile patients must use effective contraception
* HIV negative
* No AIDS
* Adequate nutritional status (total protein at least 60.0 g/L)
* No active bacterial infections (e.g., abscess or with fistula)
* No nonmalignant disease that would preclude study
* No history of alcoholism, drug addiction, or psychotic disorders that would preclude study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Prior bone marrow transplantation allowed
* At least 4 weeks since prior immunotherapy or cytokines
Chemotherapy:
* See Disease Characteristics
* Prior intensive chemotherapy with stem cell support allowed
* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or high dose carboplatin)
Endocrine therapy:
* No concurrent corticosteroids
Radiotherapy:
* At least 4 weeks since prior radiotherapy to more than 25% of bone marrow
Surgery:
* Recovered from prior surgery
* No prior solid organ transplantation
Other:
* No concurrent antiinflammatory agents including aspirin, or over the counter or prescription nonsteroidal antiinflammatory drugs
* No concurrent immunosuppressive agents
* No other concurrent investigational agents
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LifeTime Pharmaceuticals
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suzin Mayerson, PhD
Role: STUDY_CHAIR
LifeTime Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Victory Over Cancer
Rockville, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LIFETIME-LTP-99-02
Identifier Type: -
Identifier Source: secondary_id
LIFETIME-IRB-0300202
Identifier Type: -
Identifier Source: secondary_id
NCI-V00-1628
Identifier Type: -
Identifier Source: secondary_id
CDR0000068279
Identifier Type: -
Identifier Source: org_study_id